€250.30 pre-market for SRT3.DE Sartorius AG (XETRA): earnings due 03 Feb, key catalyst ahead
SRT3.DE stock opens pre-market at €250.30, down 2.30% as investors position ahead of Sartorius AG’s earnings report on 03 Feb 2026. Trading volume sits at 159,581 shares versus an average of 73,802, signaling higher-than-normal activity. The company trades on XETRA in Germany and shows a near-term technical range between €242.00 and €256.50 today. We focus on the upcoming earnings release, valuation signals, and what analysts and models say about the SRT3.DE stock outlook.
Pre-market snapshot and immediate drivers for SRT3.DE stock
Sartorius AG (SRT3.DE) is trading at €250.30, down €5.90 or -2.30%, with a pre-market open of €256.40 and yesterday’s close €256.20. Intraday low and high are €242.00 and €256.50. Volume is elevated at 159,581 versus average 73,802, giving a relative volume of 2.16, which suggests news sensitivity ahead of earnings.
Market-cap stands at €17.28B. Trailing EPS is €1.92 with a reported PE of 130.36, putting valuation well above typical healthcare peers. The stock is within €34.60 of its 52-week high €284.90 and sits comfortably above its 200-day average €221.79.
Earnings preview and key catalysts
Sartorius reports results on 03 Feb 2026; the earnings announcement is the main catalyst for SRT3.DE stock this week. Analysts will watch revenue growth, margins and management guidance for bioprocess solutions and lab products. Recent quarterly trends show mixed profitability metrics, and the market is sensitive to guidance changes.
Near-term catalysts include order intake trends in bioprocess and lab segments, margin commentary on supply-chain and pricing, and any update on capital allocation. Given current elevated volume, the print could trigger a swift re-rating if guidance misses or beats expectations.
Financials, valuation and analyst context for SRT3.DE
Sartorius shows solid revenue per share €50.95 and book value per share €55.24, but trailing metrics highlight pressure: PE reported at 130.36 and price-to-sales 4.91. Key ratios include current ratio 0.95, debt-to-equity 1.60, and free cash flow per share €4.80. The company’s net profit margin is 4.81%, while operating margin is 16.44%.
Financial growth for FY 2024 shows a revenue change of -0.44% and net income decline of -59.06%, indicating near-term earnings compression. Investors should weigh growth in bioprocess demand against high valuation multiples and leverage.
Technical picture and trading signals
Momentum indicators for SRT3.DE stock are constructive but not extreme. RSI is 59.63, MACD histogram is positive at 1.60, and ADX is 26.49, indicating a trending market. Bollinger band middle is €248.71 with an upper band at €266.66 and lower band at €230.76, placing price near the mid-band.
Short-term support lies near €242.00 and resistance near €266.66. Average true range is €6.84, useful for short-term stop placement. Traders should note higher-than-average volume, which amplifies moves around the earnings release.
Meyka AI grade, model forecast and price targets
Meyka AI rates SRT3.DE with a score out of 100: 66.28/100 — Grade B (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects moderate confidence in Sartorius’s business but flags valuation and leverage concerns.
Meyka AI’s forecast model projects a 12‑month target of €160.58, which implies a -35.85% downside from the current €250.30. Shorter-horizon monthly and quarterly projections are €215.80 and €213.24 respectively. Forecasts are model-based projections and not guarantees. Our base-case analyst price target range remains €180.00–€290.00 depending on post-earnings guidance and margin recovery.
Risks, opportunities and sector context
Risks for SRT3.DE stock include continued margin pressure, high leverage (debt-to-equity 1.60), and earnings volatility. Inventory days are elevated at 160.54, which could weigh on working capital if demand slows. A high PE and low current ratio add valuation and liquidity risk.
Opportunities include sustained demand for bioprocess equipment and consumables, accelerating lab automation adoption, and improved free cash flow (FCF yield 1.92%) if sales recover. In the Healthcare sector, peers show average PE around 33.55, so Sartorius’s premium implies growth expectations that must be met to justify the multiple.
Final Thoughts
SRT3.DE stock trades pre-market at €250.30 with elevated volume as investors price in Sartorius AG’s earnings on 03 Feb 2026. The company has durable franchise strengths in bioprocess solutions, but recent financials show compressed earnings and higher leverage. Valuation is rich with a PE of 130.36, while key ratios such as current ratio 0.95 and debt-to-equity 1.60 raise short-term risk. Meyka AI’s forecast model projects €160.58 for the 12‑month horizon, implying -35.85% from today’s price; forecasts are model‑based projections and not guarantees. For investors, the next earnings print and management guidance will likely determine whether the market focuses on growth potential or valuation repair. Use a measured approach: consider position sizing and stops, watch order intake and margin commentary, and compare moves to sector peers before changing allocation. Meyka AI provides this as AI-powered market analysis to help frame the SRT3.DE stock decision
FAQs
When does Sartorius (SRT3.DE) report earnings and why does it matter?
Sartorius reports on 03 Feb 2026. The result matters because guidance, order intake and margin commentary can drive sharp moves in SRT3.DE stock given current elevated volume and stretched valuation.
What is Meyka AI’s current rating for SRT3.DE stock?
Meyka AI rates SRT3.DE with a score out of 100 at 66.28, grade B with a HOLD suggestion. The grade factors in benchmark, sector, growth and key metrics.
What price target and downside does the Meyka forecast show for SRT3.DE?
Meyka AI’s forecast model projects a 12‑month price of €160.58, implying -35.85% from the current €250.30. Forecasts are model-based projections and not guarantees.
Which metrics should investors watch in the earnings report?
Watch revenue growth, gross and operating margins, order intake in bioprocess and lab segments, EPS versus guidance, and any cash‑flow or capex updates that affect valuation of SRT3.DE stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
